GW24-e3085 The dual PPAR alpha/gamma agonist aleglitazar has a beneficial effect on atherogenic dyslipidemia in patients with type 2 diabetes | Heart

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BCS

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Citation Tools

Cardiovascular Disease Clinical Research

Related Pharmaceutical Clinical Research

GW24-e3085 The dual PPAR alpha/gamma agonist aleglitazar has a beneficial effect on atherogenic dyslipidemia in patients with type 2 diabetes

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Herz M, Malmberg K, Hanefeld M, et al

GW24-e3085 The dual PPAR alpha/gamma agonist aleglitazar has a beneficial effect on atherogenic dyslipidemia in patients with type 2 diabetes

Heart 2013;99:A248.